Clinical trials
Refractory Indolent Non-Hodgkin Lymphoma clinical trials
Below are recruiting refractory indolent non-hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 44 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07123454RecruitingPhase 1/Phase 2
Study of AZD4512 for relapsed or refractory B-cell lymphoma
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
Irvine, CaliforniaAges 18 years+ - NCT07365306RecruitingPhase 2
Epcoritamab with chemo before stem cell transplant for DLBCL
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Duarte, CaliforniaAges 18 years+ - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT07451054RecruitingPhase 1
Stem cells plus CAR T-cells for lymphoma
This trial tests a new treatment that combines your own stem cells with special immune cells (CAR T-cells) that target a marker called CD45 on lymphoma cells. It may help people whose lymphoma has not responded to multiple prior therapies.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06552559RecruitingPhase 1/Phase 2
Selinexor plus ICE chemo for brain-involved B-cell lymphoma
This trial tests a new drug, selinexor, combined with standard ICE chemotherapy for patients whose B-cell non-Hodgkin lymphoma has spread to the brain or spinal cord. It aims to see if adding selinexor improves treatment results.
SeoulAges 18 years+ - NCT06209619RecruitingPhase 1
Study of CC-99282 plus rituximab after CAR-T for lymphoma
This trial tests combining an experimental pill (CC-99282) with the immunotherapy drug rituximab for people with B-cell non-Hodgkin's lymphoma whose cancer did not fully respond to CAR-T cell therapy. The goal is to improve results after CAR-T.
Columbus, OhioAges 18 years+ - NCT06021678RecruitingPhase 1/Phase 2
EX103 for relapsed or refractory CD20-positive lymphoma
This trial tests a new drug called EX103 for people whose non-Hodgkin lymphoma (a cancer of the immune system) has come back or not responded to earlier treatments. The goal is to see if EX103 is safe and can shrink tumors.
Zhengzhou, HenanAges 18 years+ - NCT05755087RecruitingPhase 1
Tegavivint for relapsed or hard-to-treat lymphoma patients
This Phase 1 trial tests tegavivint, a new investigational medicine, for certain types of aggressive B-cell lymphoma that have come back or did not respond to prior treatment. It may help shrink the lymphoma and learn how safe and effective the drug is in this setting.
Columbus, OhioAges 18 years+ - NCT03571568RecruitingPhase 1/Phase 2
Study of BI-1206 plus rituximab, with or without acalabrutinib
This early-phase study tests BI-1206 combined with rituximab, and possibly adds acalabrutinib, in people with certain slow-growing B-cell lymphomas that have come back or did not respond to prior treatment. The goal is to see whether this treatment approach shrinks lymphoma safely and effectively.
Atlanta, GeorgiaAges 18 years+ - NCT06386315RecruitingPhase 2
Lower dose radiation for slow-growing lymphoma
This trial tests whether giving a lower dose of radiation than usual works well for people with slow-growing B-cell lymphomas. It aims to reduce side effects while still controlling the disease.
Scottsdale, ArizonaAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Gilbert, ArizonaAges 18 years+ - NCT07101705RecruitingEarly Phase 1
Testing OriV508 for blood cancers that haven't responded to treatment
This study tests a new treatment called OriV508 for people with blood cancers (multiple myeloma or aggressive B-cell lymphoma) that have not responded to at least two previous therapies. It aims to see if the treatment is safe and helps shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT07620314RecruitingPhase 1
Testing a new cell therapy for B-cell lymphoma
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT03223610RecruitingPhase 1/Phase 2
ViPOR treatment for relapsed or hard-to-treat lymphoma
This Phase 1/2 trial tests a combination of several medicines (venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid) for lymphoma that has come back or did not respond. It aims to shrink tumors safely and improve responses in people with specific types of B-cell lymphoma.
Bethesda, MarylandAges 18–120 - NCT04223765RecruitingPhase 1
Testing a new CAR T-cell treatment for kappa cancers
This Phase 1 trial studies a lab-made immune therapy (CAR T cells) that targets “kappa” markers on certain lymphomas and CLL/SLL. It’s for people whose cancer has come back or didn’t respond to standard treatments, aiming to improve control of the disease.
Chapel Hill, North CarolinaAges 18 years+ - NCT04545762RecruitingPhase 1
Anti-CD19 CAR-T for certain relapsed lymphoma
This Phase 1 study tests an anti-CD19 CAR-T cell treatment in adults with specific types of relapsed or treatment-resistant non-Hodgkin lymphoma. It may help by finding and attacking lymphoma cells that carry the CD19 marker, but it’s early-stage and eligibility is strict.
San Francisco, CaliforniaAges 18 years+ - NCT05093335RecruitingEarly Phase 1
PET scan test for CXCR4 in many relapsed cancers
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
New York, New YorkAges 18 years+ - NCT05418088RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell cancers
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Columbus, OhioAges 2 years+ - NCT05798897RecruitingPhase 1
Study drug MT-601 for relapsed lymphoma patients
This early-phase trial tests MT-601 (an experimental treatment) in adults whose lymphoma has come back or didn’t respond to standard treatments. The study mainly checks safety, and it also looks for early signs that the treatment can shrink tumors.
Duarte, CaliforniaAges 18–100 - NCT05842707RecruitingPhase 1/Phase 2
Cord blood CAR cells for hard-to-treat B-cell lymphoma
This Phase 1/2 study tests cord blood–derived CAR NK cells that are designed to attack lymphoma cells marked with CD19 and/or CD70. It is for people whose B-cell non-Hodgkin lymphoma has come back or did not respond to prior treatment, including CAR-T when applicable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06013423RecruitingPhase 2
Cord blood transplant with chemo and radiation for high-risk blood cancers
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Seattle, WashingtonAges 6 months–65 years - NCT06026319RecruitingPhase 1
CAR T cells targeting CD79b and CD19 for non-Hodgkin lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It's for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments.
Boston, MassachusettsAges 18 years+ - NCT06208735RecruitingPhase 1
CLIC-2201 for relapsed or refractory B-cell cancers
This early-phase trial tests a new treatment called CLIC-2201 for people whose B-cell lymphoma or leukemia has not responded to other treatments or has come back. It aims to see if this therapy can help when other options have failed.
Calgary, AlbertaAges 1 year+ - NCT06313957RecruitingPhase 1
Study of LUCAR-20SP for relapsed B-cell lymphoma
This trial tests a new treatment called LUCAR-20SP for people with certain types of B-cell lymphoma that have come back or not responded to prior therapy. The drug is a type of CAR-T therapy that targets the CD20 protein on lymphoma cells.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Refractory Indolent Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory indolent non-hodgkin lymphoma?
- Yes. Clin2 currently lists 44 recruiting refractory indolent non-hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory indolent non-hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory indolent non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Refractory Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Non-Hodgkin Lymphoma Refractory/ Relapsed
- Indolent Non-hodgkin Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Indolent B-Cell Non-Hodgkin Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Recurrent Indolent Non-Hodgkin Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.